-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Banner Life Sciences LLC today announced that the U.SFood and Drug Administration (FDA) has approved its BAFIERTAM (polymethylamine) release capsule for the treatment of recurrent multiple sclerosis (MS)FACNS FAASM physician Daniel Wynn said: 'As a practicing neurologist treating MS patients, I am encouraged that the lower dose of BAFIERTAM (funtric sulpherate) is comparable to tecfidera and may improve the patient's gastrointestinal tolerance'
BAFIERTAM is a prescription drug used to treat recurrent multiple sclerosis (MS) in adults, including clinically isolated syndrome, recurrent type, and active secondary developmentrecurrent-remission multiple sclerosis (RRMS) is the most common form of MS, accounting for 85% of MS patients, an estimated 2 million people worldwide, and is a debilitating autoimmune diseaseTreatment options for RRMS focus on symptom management, slowing disease progression and reducing recurrence